Invesco S&P Small Cap Healthcare

Corcept Therapeutics Inc Executives Sean Maduck Sold $1.6 Million in Stocks

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

William Blair Analyst Maintains Buy Rating on TransMedics Group

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Director Reports Sale of Company Common Stock

Alkermes Executives Disposed of Company Stocks

Arrowhead Pharmaceuticals to Participate in Multiple Medical Conferences in December 2025 and Present on RNAi Therapies

Arrowhead Pharmaceuticals to Attend Multiple Healthcare Conferences in December 2025 to Showcase Plozasiran Progress

DeepHealth Launches Next-Generation Imaging Informatics and Clinical AI Solutions

B. Riley Maintains Arrowhead Pharmaceuticals 'Strong Buy' Rating, Projects EPS at $6.48

Protagonist Therapeutics Sees Significant Revenue Growth with Janssen Collaboration

TransMedics Executives Sell $435,660 in Stock

Glaukos Corporation CFO Reports Sale of Common Stock

TransMedics Group Inc. Official Disposes of Common Stock

Arrowhead Pharmaceuticals Reports Better-than-Expected Q4 Earnings, Shares Soar

RBC Capital Analyst Reiterates Buy Rating on Arrowhead Pharmaceuticals

ArrowHead Pharma released FY2025 Q4 earnings on November 25 After-Market EST, actual revenue USD 256.47 M (forecast USD 157.31 M), actual EPS USD -0.1741 (forecast USD -0.2954)

ArrowHead Pharma released FY2025 Annual Earnings on November 25 After-Market (EST), actual revenue USD 829.45 M (forecast USD 757.44 M), actual EPS USD -0.0121 (forecast USD -0.0075)

Arrowhead Pharmaceuticals Sees First FDA Approval and Enters Commercial Stage

Arrowhead Pharmaceuticals earns $200 million milestone payment from Sarepta Therapeutics

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

RDNT

RadNet, Inc. filed a shelf registration statement and prospectus supplement with the SEC on December 4, 2025. The filing aims to maintain an effective shelf registration statement and registers for resale up to 73,567 shares of common stock. The resale prospectus supplement supersedes prior filings, with a legal opinion by Reed Smith LLP attached as Exhibit 5.1.

TradingView

Radnet

RadNet Files Shelf Registration Statement and Prospectus Supplement

CORT

Corcept Therapeutics Insider Sold Shares Worth $1,590,490, According to a Recent SEC Filing

marketscreener

Corcept Therap

Corcept Therapeutics Insider Sold Shares Worth $1,590,490, According to a Recent SEC Filing

PTCT

PTC Therapeutics CEO Matthew B. Klein sold 3,428 shares worth $271,051 on December 3, 2025. The company has seen significant stock activity due to strong Q3 earnings and the launch of Sephience. RBC Capital downgraded the stock, while Goldman Sachs and TD Cowen raised their price targets. Despite challenges, the earnings call was positive. TipRanks’ AI Analyst rates PTCT as Outperform, citing strong technical indicators and favorable valuation.

Tip Ranks

PTC Therap

PTC Therapeutics CEO Makes Significant Stock Sale!

Officer Sean Maduck of Corcept Therapeutics Inc sold 20,000 shares worth $1.6 million, as disclosed in a Form 4 filed with the SEC. The sale was part of a prearranged trading plan (10b5-1). Ending holdings are 117,896 shares. The Washington Service offers insider trading analysis and data services.

Reuters

Officer Maduck Sells 20,000 ($1.6M) Of Corcept Therapeutics Inc [CORT]

Officer Lyon Joseph Douglas of Corcept Therapeutics Inc sold 5,000 shares for $397,632 as part of a prearranged trading plan. The transaction was disclosed in a Form 4 filed with the SEC. The officer also exercised options and surrendered shares to cover costs and tax liabilities, ending with 10,523 shares directly held.

Officer Lyon Sells 5,000 ($397.6K) Of Corcept Therapeutics Inc [CORT]

Corcept Therapeutics Inc's CFO, Mokari Atabak, surrendered 118 shares back to the company on December 2, 2025, to cover option exercise costs and tax liabilities. The shares were valued at $9,414, with a price of $79.78 per share. Mokari's direct holdings now total 14,559 shares.

CFO Mokari Surrenders 118 Of Corcept Therapeutics Inc [CORT]

Guyer William Officer of Corcept Therapeutics Inc [CORT] filed a Form 4/A on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:DateTransactionSharesPriceValue11/17/25Gift5,287$0.00N/A11/25/25Sale4,500$80.90$364,070Ending Holdings: 787 (0 - Direct, 787 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Guyer Sells 4,500 ($364.1K) Of Corcept Therapeutics Inc [CORT]-Amended

Robb Gary Charles, an officer of Corcept Therapeutics Inc, surrendered 148 shares back to the company to cover option exercise costs and tax liabilities. The transaction was filed with the SEC on December 3, 2025, with the shares valued at $11,807. His ending holdings are 37,052 shares, split between direct and indirect ownership.

Officer Robb Surrenders 148 Of Corcept Therapeutics Inc [CORT]

Joseph K. Belanoff, CEO of Corcept Therapeutics, reported the disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This information is for informational purposes only and not financial advice.

Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares

CEO Matthew B. Klein of PTC Therapeutics Inc. filed a Form 4 with the SEC, disclosing changes in ownership. On December 1, 2025, he exercised 7,812 shares at $0.00, and on December 2, 2025, he surrendered 3,428 shares at $79.07, valued at $271,052, under a prearranged trading plan (10b5-1). Ending holdings are 349,964 shares directly.

CEO Klein Acquires 4,384 Of PTC Therapeutics Inc [PTCT]

ARWR

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached a new 52-week high after HC Wainwright raised its price target from $80 to $85, maintaining a buy rating. The stock traded as high as $59.27, closing at $58.53. Other analysts have also issued positive ratings, contributing to the stock's rise. Insiders sold shares recently, and institutional investors have been active in trading. Arrowhead Pharmaceuticals has a market cap of $7.93 billion and develops medicines for intractable diseases.

Market Beat

ArrowHead Pharma

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade

Emma Reeve, Director of PTC Therapeutics Inc, filed a Form 144 with the SEC on December 3, 2025, to sell 733 shares of restricted securities through Fidelity Brokerage Services under a prearranged trading plan (10b5-1).

Dir Reeve Files To Sell 733 Of PTC Therapeutics Inc [PTCT]

CIFR

Amid market volatility, TipRanks' Technical Analysis Screener identifies three 'Strong Buy' stocks: Corcept Therapeutics (CORT), Axis Capital (AXS), and Cipher Mining (CIFR). These stocks show bullish momentum and potential short- to mid-term upside, supported by strong Wall Street analyst ratings. TipRanks offers a Cyber Monday sale with 60% off its Premium service for data-backed insights and research tools.

Cipher Mining

Axis Capital

3 'Strong Buy' Stocks Backed by Technical Analysis

Wells Fargo analyst Tiago Fauth maintained a Buy rating on PTC Therapeutics with a price target of $93.00. Fauth, who focuses on the Healthcare sector, has an average return of 11.7% and a 49.59% success rate. Additionally, William Blair’s Sami Corwin also issued a Buy rating, while Goldman Sachs maintained a Sell rating on PTC Therapeutics.

PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo

Creative Planning increased its stake in Arrowhead Pharmaceuticals by 72.5% in Q2, owning 45,662 shares valued at $721,000. Other hedge funds also adjusted their positions. Insiders sold 43,750 shares worth $1.64 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $53.33. Arrowhead's stock opened at $57.95, with a market cap of $7.87 billion.

Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR